Rebound Thrombocytosis after Induction Chemotherapy is a Strong Biomarker for Favorable Outcome in AML Patients

Rebound Thrombocytosis after Induction Chemotherapy is a Strong Biomarker for Favorable Outcome in AML Patients

Abstract. Whereas the molecular events underlying acute myeloid leukemia (AML) are increasingly identified, dynamics of hematologic recovery following induction chemotherapy remain mysterious. Platelet recovery may vary between incomplete and excess recovery among patients achieving remission. We an...

Full description

Bibliographic Details
Main Authors:	Bianca R. Schnell, Katja Seipel, Ulrike Bacher, Barbara Jeker, Beatrice U. Mueller, Yara Banz, Urban Novak, Thomas Pabst
Format:	Article
Language:	English
Published:	Wiley 2019-04-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/HS9.0000000000000180

Similar Items

Autologous Transplantation for Older Adults with AML
by: Beatrice U. Mueller, et al.
Published: (2018-09-01)

Transformed Lymphoma Is Associated with a Favorable Response to CAR-T-Cell Treatment in DLBCL Patients
by: Anna Nydegger, et al.
Published: (2021-12-01)

BeEAM High-Dose Chemotherapy with Polatuzumab (Pola-BeEAM) before ASCT in Patients with DLBCL—A Pilot Study
by: Tanja Stoffel, et al.
Published: (2022-06-01)

Low-Frequency <i>PPM1D</i> Gene Mutations Affect Treatment Response to CD19-Targeted CAR T-Cell Therapy in Large B-Cell Lymphoma
by: Katja Seipel, et al.
Published: (2023-12-01)

Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy
by: Vera Rentsch, et al.
Published: (2022-05-01)

The Evolving Treatment Landscape of AML
by: Sabine Blum, et al.
Published: (2022-03-01)

sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma
by: Katja Seipel, et al.
Published: (2022-03-01)

Correlation of Peripheral Chimeric Antigen Receptor T-cell (CAR-T Cell) mRNA Expression Levels with Toxicities and Outcomes in Patients with Diffuse Large B-cell Lymphoma
by: Christian Messerli, et al.
Published: (2023-08-01)

Evaluation of Bortezomib-BeEAM (2BeEAM) as Chemotherapy Regimen Prior to ASCT in Patients with Mantle Cell Lymphoma
by: Fabrizio Huwyler, et al.
Published: (2023-03-01)

OUTCOME OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA RELAPSING AFTER AUTOLOGOUS TRANSPLANT BEFORE AVAILABILITY OF CAR-T CELL TREATMENT
by: Ulrike Bacher, et al.
Published: (2023-04-01)

BMI1-Inhibitor PTC596 in Combination with MCL1 Inhibitor S63845 or MEK Inhibitor Trametinib in the Treatment of Acute Leukemia
by: Katja Seipel, et al.
Published: (2021-02-01)

HSP90 Inhibitor PU-H71 in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia
by: Katja Seipel, et al.
Published: (2023-08-01)

Rationale for a Combination Therapy Consisting of MCL1- and MEK-Inhibitors in Acute Myeloid Leukemia
by: Katja Seipel, et al.
Published: (2019-11-01)

Stem Cell Mobilization with Ixazomib and G-CSF in Patients with Multiple Myeloma
by: Selina Bühler, et al.
Published: (2023-01-01)

Hematopoietic Stem Cell Mobilization With Plerixafor Is Safe and Effective in Poorly Mobilizing Acute Myeloid Leukemia Patients
by: Evgenyi Shumilov, et al.
Published: (2019-04-01)

Rationale for a Combination Therapy with the STAT5 Inhibitor AC-4-130 and the MCL1 Inhibitor S63845 in the Treatment of FLT3-Mutated or TET2-Mutated Acute Myeloid Leukemia
by: Katja Seipel, et al.
Published: (2021-07-01)

Rationale for Combining the BCL2 Inhibitor Venetoclax with the PI3K Inhibitor Bimiralisib in the Treatment of IDH2- and FLT3-Mutated Acute Myeloid Leukemia
by: Katja Seipel, et al.
Published: (2022-10-01)

(2<i>R</i>,3<i>S</i>)-Dihydroxybutanoic Acid Synthesis as a Novel Metabolic Function of Mutant Isocitrate Dehydrogenase 1 and 2 in Acute Myeloid Leukemia
by: Jeffrey R. Idle, et al.
Published: (2020-10-01)

Clinical Impact of Single Nucleotide Polymorphism in CD-19 on Treatment Outcome in FMC63-CAR-T Cell Therapy
by: Katja Seipel, et al.
Published: (2023-06-01)

Thrombocytosis
by: Vitiritti M
Published: (2010-05-01)

Comparison of Melphalan Combined with Treosulfan or Busulfan as High-Dose Chemotherapy before Autologous Stem Cell Transplantation in AML
by: Ekaterina Gurevich, et al.
Published: (2022-02-01)

Blinatumomab in Relapsed/Refractory Burkitt Lymphoma
by: Jeanne Bohler, et al.
Published: (2022-12-01)

Clonal Hematopoiesis after Autologous Stem Cell Transplantation Does Not Confer Adverse Prognosis in Patients with AML
by: Alexander D. Heini, et al.
Published: (2021-06-01)

Experiences with Glofitamab Administration following CAR T Therapy in Patients with Relapsed Mantle Cell Lymphoma
by: Alexander D. Heini, et al.
Published: (2022-09-01)

Genetic background of thrombocytosis in mice mimicking hereditary thrombocytosis in humans
by: Hiroyuki Kimura, et al.
Published: (2023-12-01)

Comprehensive Laboratory Diagnostic Workup for Patients with Suspected Intraocular Lymphoma including Flow Cytometry, Molecular Genetics and Cytopathology
by: Evgenii Shumilov, et al.
Published: (2022-01-01)

Efficacy and Safety of High-Dose Chemotherapy with Treosulfan and Melphalan in Multiple Myeloma
by: Cédric Gillich, et al.
Published: (2023-05-01)

A single-centre cohort of patients with systemic light chain AL-amyloidosis treated with conventional chemotherapy or with high-dose chemotherapy and autologous stem cell transplantation
by: Joelle Raschle, et al.
Published: (2014-02-01)

Combining BeEAM with Brentuximab Vedotin for High-Dose Therapy in CD30 Positive Lymphomas before Autologous Transplantation—A Phase I Study
by: Christian Rausch, et al.
Published: (2022-09-01)

BeEAM Conditioning including High-Dose Bendamustine before Autologous Stem Cell Transplantation Is Safe and Effective in Patients with Waldenstrom’s Macroglobulinemia
by: Alexander D. Heini, et al.
Published: (2023-03-01)

An Approach to the Investigation of Thrombocytosis: Differentiating between Essential Thrombocythemia and Secondary Thrombocytosis
by: Ala Almanaseer, et al.
Published: (2024-01-01)

The Cellular p53 Inhibitor MDM2 and the Growth Factor Receptor FLT3 as Biomarkers for Treatment Responses to the MDM2-Inhibitor Idasanutlin and the MEK1 Inhibitor Cobimetinib in Acute Myeloid Leukemia
by: Katja Seipel, et al.
Published: (2018-05-01)

ESSENTIAL THROMBOCYTOSIS IN CHILDREN
by: Canan ALBAYRAK, et al.
Published: (2021-11-01)

To rebound or not to rebound
by: Bethany A Stahl, et al.
Published: (2017-10-01)

Designing a Scoring System for Differential Diagnosis From Reactive Thrombocytosis and Essential Thrombocytosis
by: Chih-Lung Shen, et al.
Published: (2021-12-01)

Anesthesia for a patient with thrombocytosis
by: T V Bharath Kumar, et al.
Published: (2013-01-01)

Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patients
by: Dilara Akhoundova Sanoyan, et al.
Published: (2023-04-01)

Systemic mastocytosis with an associated hematological neoplasms: One or two entities?
by: Linet Njue, et al.
Published: (2020-07-01)

Novel Adaptive T-Cell Oncological Treatments Lead to New Challenges for Medical Emergency Teams: A 2-Year Experience From a Tertiary-Care Hospital in Switzerland
by: Anna Sarah Messmer, MD, et al.
Published: (2021-10-01)

The Msi2 protein expression positive correlation with favorable cytogenetics findings in AML
by: Bakheet, Omayma Saad Eldeen, et al.
Published: (2017)